Matrix Partners China Leads $14M Round In Chinese Biotech Firm Ennovabio

Shanghai Ennovabio Pharmaceutical Co., Ltd., a new drug research and development start-up company, announced that it has completed a Series A financing of nearly RMB100 million (US$14 million). Matrix Partners China led the investment, and existing shareholder Highlight Capital also joined.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

LEAVE A REPLY